|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.
|
29626488 |
2018 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Genetic deletion of Mst1 and Mst2 in hepatocytes (DKO) led to HCC development, highly upregulated <i>Mcp1</i> expression and massive infiltration of macrophages with mixed M1 and M2 phenotypes.
|
28866620 |
2018 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<i>Mst1/2</i> KO and <i>Sav1</i> KO models best resemble human HCC with hepatic stem cell characteristics.
|
30082483 |
2018 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Phospho-TAZ-negativity and nYAP-positivity were almost exclusively and MST1/2 exclusively detected in HCC.
|
27276915 |
2017 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
However, how the expression of MST1 was regulated in the progression of HCC remains largely unknown.
|
28823082 |
2017 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Removal of the mammalian Hippo kinase Mst1 and Mst2 in hepatocytes leads to rapid hepatocellular carcinoma (HCC) formation, indicating that the Hippo signaling pathway is a critical gatekeeper that restrains abnormal growth in hepatocytes.
|
27881216 |
2017 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that STAT3 in hepatocytes is dispensable for HCC formation when mammalian sterile 20-like kinase 1 and 2 (Mst1 and Mst2) were removed.
|
27869648 |
2017 |
|
Liver carcinoma
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
|
27765911 |
2016 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
HOXA9 methylation was further validated by Q-MSP in two independent set of clinical samples including 100 HCC and paired non-tumor tissues.
|
24681432 |
2014 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Expression of exogenous NORE1B, a tumor suppressor commonly lost in HCC tumors (~56% of our cohort), was sufficient to suppress the growth promotion of full-length Mst1.
|
23347832 |
2013 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
DNA methylation of SOX17 was analyzed in 62 human HCC tissues and HCC cell lines by MSP.
|
20716954 |
2011 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mst1/2 inhibition of Yap1 is an important pathway for tumor suppression in liver relevant to human HCC.
|
19878874 |
2009 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These results demonstrated the clinical usefulness and effectiveness of peripheral blood RTQ-MSP for detecting and monitoring HCC after treatment.
|
12631605 |
2003 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
An increase in HGFLP could be the result of inflammation and/or tissue injury and its overexpression may prove to be useful as an indicator of hepatoma.
|
10076051 |
1999 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|